| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A biobank perspective on use of tissue samples donated by trial participants
|
Speirs, Valerie
|
|
|
23 |
5 |
p. e205
|
article
|
| 2 |
Accelerated approval requirements for lurbinectedin
|
Benjamin, David J
|
|
|
23 |
5 |
p. e206
|
article
|
| 3 |
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial
|
Hussain, Syed A
|
|
|
23 |
5 |
p. 650-658
|
article
|
| 4 |
Biden's proposed investment in cancer research sparks concerns
|
Das, Manjulika
|
|
|
23 |
5 |
p. 576
|
article
|
| 5 |
Bridging the equity gap in patient education: the biliary tract cancer BABEL project
|
Casolino, Raffaella
|
|
|
23 |
5 |
p. 568-570
|
article
|
| 6 |
Cancer care crisis in the Palestinian territories
|
Das, Manjulika
|
|
|
23 |
5 |
p. 575
|
article
|
| 7 |
Carcinogenicity of cobalt, antimony compounds, and weapons-grade tungsten alloy
|
Karagas, Margaret R
|
|
|
23 |
5 |
p. 577-578
|
article
|
| 8 |
Correction to Lancet Oncol 2021; 22: 1250–64
|
|
|
|
23 |
5 |
p. e207
|
article
|
| 9 |
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
|
Nitz, Ulrike
|
|
|
23 |
5 |
p. 625-635
|
article
|
| 10 |
Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trial
|
Heindel, Walter
|
|
|
23 |
5 |
p. 601-611
|
article
|
| 11 |
Equity in national cancer control plans in the region of the Americas
|
Loggetto, Patrícia
|
|
|
23 |
5 |
p. e209-e217
|
article
|
| 12 |
Failure to tackle workforce shortages threatens cancer survival progress in England
|
Wilkinson, Emma
|
|
|
23 |
5 |
p. e208
|
article
|
| 13 |
FDA decisions on new oncological drugs
|
Li, Guanqiao
|
|
|
23 |
5 |
p. 583-585
|
article
|
| 14 |
FDA decisions on new oncological drugs
|
Benjamin, David J
|
|
|
23 |
5 |
p. 585-586
|
article
|
| 15 |
G-CSF-induced carotid inflammation
|
Singh, Harshabad
|
|
|
23 |
5 |
p. e235
|
article
|
| 16 |
Has Pakistan failed to roll back HPV?
|
Awan, Usman Ayub
|
|
|
23 |
5 |
p. e204
|
article
|
| 17 |
High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial
|
Zapatero, Almudena
|
|
|
23 |
5 |
p. 671-681
|
article
|
| 18 |
IAEA reviews plan to release treated water from Fukushima
|
Das, Manjulika
|
|
|
23 |
5 |
p. 574
|
article
|
| 19 |
Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group
|
Morana, Giovanni
|
|
|
23 |
5 |
p. e218-e228
|
article
|
| 20 |
Is tailored systemic therapy in renal cell carcinoma realistic?
|
Kondo, Tsunenori
|
|
|
23 |
5 |
p. 555-557
|
article
|
| 21 |
Long-term versus short-term androgen deprivation combined with EBRT for unfavourable prostate cancer
|
Crook, Juanita
|
|
|
23 |
5 |
p. 558-560
|
article
|
| 22 |
Maintenance endocrine therapy plus bevacizumab for advanced or metastatic breast cancer
|
Quesada, Stanislas
|
|
|
23 |
5 |
p. 557-558
|
article
|
| 23 |
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial
|
Vano, Yann-Alexandre
|
|
|
23 |
5 |
p. 612-624
|
article
|
| 24 |
Oncologists in social media—what are the limits?
|
The Lancet Oncology,
|
|
|
23 |
5 |
p. 553
|
article
|
| 25 |
Ongoing crisis in Ukraine continues to affect cancer care
|
Burki, Talha Khan
|
|
|
23 |
5 |
p. 573
|
article
|
| 26 |
Patient-reported outcomes: what really matters to patients?
|
Hasanov, Elshad
|
|
|
23 |
5 |
p. e198
|
article
|
| 27 |
Patient-reported outcomes: what really matters to patients? – Authors' reply
|
Cella, David
|
|
|
23 |
5 |
p. e199
|
article
|
| 28 |
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
|
Diaz Jr, Luis A
|
|
|
23 |
5 |
p. 659-670
|
article
|
| 29 |
Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study
|
Thiruchelvam, Paul T R
|
|
|
23 |
5 |
p. 682-690
|
article
|
| 30 |
Proud about PRADA: radiotherapy before deep inferior epigastric perforator flap reconstruction
|
Kaidar-Person, Orit
|
|
|
23 |
5 |
p. 560-562
|
article
|
| 31 |
Re-engaging EU citizens with national screening programmes and cancer diagnosis post-pandemic
|
Baird, Anne-Marie
|
|
|
23 |
5 |
p. 566-567
|
article
|
| 32 |
Resilience and perseverance under siege: providing cancer care during the invasion of Ukraine
|
Kizub, Darya
|
|
|
23 |
5 |
p. 579-583
|
article
|
| 33 |
Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): an International Cancer Benchmarking Partnership (ICBP) population-based study
|
McPhail, Sean
|
|
|
23 |
5 |
p. 587-600
|
article
|
| 34 |
Screening for breast cancer brain metastases
|
Knisely, Jonathan
|
|
|
23 |
5 |
p. e200
|
article
|
| 35 |
Screening for breast cancer brain metastases – Authors' reply
|
Yan, Min
|
|
|
23 |
5 |
p. e201
|
article
|
| 36 |
Should tomosynthesis replace mammography for breast cancer screening?
|
Houssami, Nehmat
|
|
|
23 |
5 |
p. 554-555
|
article
|
| 37 |
Sodium thiosulfate for prevention of cisplatin-induced hearing loss: updated survival from ACCL0431
|
Orgel, Etan
|
|
|
23 |
5 |
p. 570-572
|
article
|
| 38 |
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial
|
Saji, Shigehira
|
|
|
23 |
5 |
p. 636-649
|
article
|
| 39 |
The DRUG Access Protocol: access inequality and European harmonisation
|
Polak, Tobias B
|
|
|
23 |
5 |
p. e202
|
article
|
| 40 |
The DRUG Access Protocol: access inequality and European harmonisation – Authors' reply
|
van Waalwijk van Doorn-Khosrovani, Sahar Barjesteh
|
|
|
23 |
5 |
p. e203
|
article
|
| 41 |
The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint
|
Richardson, Nicholas C
|
|
|
23 |
5 |
p. 563-566
|
article
|
| 42 |
Time to deterioration of symptoms or function using patient-reported outcomes in cancer trials
|
Fiero, Mallorie H
|
|
|
23 |
5 |
p. e229-e234
|
article
|
| 43 |
War-torn Afghanistan and cancer care: where to focus?
|
Awan, Usman Ayub
|
|
|
23 |
5 |
p. 562-563
|
article
|
Journal description